



NEWS RELEASE

MDxHealth Biomarkers Used in Successful Testing of Predictive Biosciences' Bladder Cancer Assay

Data Presented at GTCbio's Oncology Biomarkers Conference

DURHAM, NC, and LIEGE, BELGIUM – January 27, 2011 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that its partner, Predictive Biosciences, will present data from testing of a non-invasive bladder cancer diagnostic assay that incorporates two MDxHealth DNA methylation biomarkers, NID2 and TWIST.

Data being presented today by Predictive Biosciences at GTCbio's Oncology Biomarkers Conference in San Diego, USA demonstrates that the combination of four biomarkers (including protein, genetic and DNA methylation markers) in its CertNDx™ Bladder Cancer Assay resulted in 94 percent sensitivity, with a 99.5 percent negative predictive value (NPV), the probability that a patient who has tested negative for cancer is disease free. This urine based test is being developed as a tool to aid the clinical management of bladder cancer. In the clinic, patients who are tested and shown to be disease free may then be excluded from undergoing invasive procedures.

"Predictive Biosciences's approach of combining protein, genetic and DNA methylation markers into a single test is demonstrating very good results in bladder cancer and we are proud of the use of our NID2 and TWIST methylation markers in a much needed product that could help patients avoid unnecessary invasive tests," said Dr. Jan Groen, CEO of MDxHealth.

During the conference on January 28, Prof. Dr. Wim Van Criekinge, Vice President Science and Technology at MDxHealth will give a presentation titled "Methylation Based Biomarkers for Predictive and Prognostic Use".

About MDxHealth

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company's tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research center such as Johns Hopkins University, Duke University, Lovelace Respiratory Research Institute, Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Qiagen, and other industry leaders. More information can be found on the Company website : www.mdxhealth.com or on Twitter at the following address : www.twitter.com/mdxhealth

For more information:

Dr. Jan Groen, CEO
MDxHealth
+32 4 364 20 70

Hans Herklots
Capricorn One
+41 79 598 7149

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation